[1]肖 岚,朱 宏,张 婷,等.董克礼教授治疗原发性肝癌临床经验*[J].陕西中医,2020,(11):1639-1642.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
　XIAO Lan,ZHU Hong,ZHANG Ting,et al.Experience of professor DONG Keli for treating primary liver cancer[J].,2020,(11):1639-1642.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
点击复制

董克礼教授治疗原发性肝癌临床经验*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年11期
页码:
1639-1642
栏目:
名老中医经验
出版日期:
2020-11-05

文章信息/Info

Title:
Experience of professor DONG Keli for treating primary liver cancer
作者:
肖 岚1; 朱 宏1; 张 婷1; 任 丹1; 李若梦1; 绍范雷2
1.中南大学湘雅三医院(长沙 410013); 2.河南中医药大学第一附属医院(郑州 450004)
Author(s):
XIAO Lan; ZHU Hong; ZHANG Ting; et al.
The Third Xiangya Hospital of Central South University(Changsha 410013)
关键词:
肝癌;  本虚标实;  扶正祛邪;  活血化瘀;  清热解毒
Keywords:
Liver cancer;  Deficiency of the origin;  Strengthening the body and removing pathogenic factors;  Promoting blood circulation and removing blood stasis;  Clearing heat and detoxification
分类号:
R735.7
DOI:
DOI:10.3969/j.issn.1000-7369.2020.11.032
文献标志码:
A
摘要:
原发性肝癌是病死率较高的恶性肿瘤之一,其发病率及病死率高。现代医学治疗肝癌的主要手段有肿瘤切除、化学治疗、放射治疗、介入治疗以及免疫治疗等,但肝癌恶性程度高,发展变化快,预后往往不理想。中医药治疗肝癌术后、放化疗后患者及中晚期肝癌患者,不良反应小,不容易产生耐药,能提高机体免疫力,明显改善患者生存质量、延长生存期。董克礼教授在原发性肝癌的中医辨证治疗上有独特的诊治思路和辨治方法,临床疗效突出,他认为本虚标实为原发性肝癌的根本病机,强调扶正祛邪原则,治疗上重视活血化瘀和清热解毒之法,善于辨证辨病治疗肝癌。本文总结了董教授治疗原发性肝癌的经验。
Abstract:
The incidence rate and mortality of primary liver cancer are high.The main treatment methods of modern medicine for liver cancer include tumor resection,chemotherapy,radiotherapy,interventional therapy and immunotherapy.However,the prognosis of liver cancer is often unsatisfactory due to its high degree of malignancy,rapid development and change.Traditional Chinese medicine treatment of liver cancer patients after surgery,radiotherapy and chemotherapy,and patients with advanced liver cancer,less toxic side effects,not easy to produce drug resistance,can improve the body immunity,significantly improve the quality of life of patients,prolong the survival period.Professor DONG Keli has unique ideas and methods of diagnosis and treatment in TCM dialectical treatment of primary liver cancer,with outstanding clinical efficacy.He believes that the deficiency of the origin is the fundamental pathogenesis of primary liver cancer.He emphasizes the principle of strengthening the body and removing pathogenic factors,and pays attention to the methods of promoting blood circulation and removing blood stasis,clearing heat and detoxification,which is good at treating liver cancer based on syndrome differentiation and disease differentiation.This paper summarizes Professor DONG's experience in the treatment of primary liver cancer and clinical medical records with good curative effect.

参考文献/References:

[1] Akinyemiju T,Abera S,Ahmed M,et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global,reginal,and national level[J].JAMA Oncology,2017,3(12):1683.
[2] Wang FS,Fan JG,Zhang Z,et al.The global burden of liver disease:the major impact of China[J].Hepatology,2014,60(6):2099-2108.
[3] 李 珣,张祥林.肝动脉化疗栓塞联合恩替卡韦对原发性肝癌治疗效果及对患者血清中恶性肿瘤特异性生长因子的影响[J].陕西医学杂志,2019,48(7):873-875.
[4] 江南雪,熊墨年,唐晓玲.原发性肝癌的中医治疗进展[J].实用中西医结合临床,2016,16(10):84-86.
[5] 周小舟,冯文杏,孙新锋,等.原发性肝癌中医宏观辨证传承及微观辨证学创新与发展[J].湖南中医药大学学报,2018,38(8):845-848.
[6] 胡 琦,谭小宁,余 娜,等.臭牡丹总黄酮介导Wnt/β-catenin信号转导诱导人肝癌细胞HepG2的凋亡[J].世界中医药,2016,11(6):954-957.
[7] 王 莹.半枝莲多糖抗肝癌作用的研究[J].现代养生,2016,32(10):53.
[8] 江灵礼,苗明三.凌霄花化学药理及临床应用特点探讨[J].中医学报,2014,29(194):1016-1018.
[9] 叶 勇,涂先琴,宋兴文,等.水杨梅根提取物的体外抗肿瘤活性[J].浙江中医药大学学报,2007,31(3):372-373.
[10] 欧 莉.中药凤尾草的研究进展[J].中医药导报,2008,14(3):92-93.
[11] 王文芳,陈 岩,王智勇.凤尾草提取物体内抗肿瘤作用的研究[J].中国中医药科技,2013,20(3):259-260.
[12] 韦金育,李 延,韦 涛,等.50种广西常用中草药、壮药抗肿瘤作用的筛选研究[J].广西中医学院学报,2003,6(4):3-7.
[13] 宋秋佳,卢文丽,潘志强.中药复方及单味药提取物抗肝癌细胞侵袭转移分子机制[J].中西医结合肝病杂志,2020,30(3):283-288.
[14] 刘嘉辉,吕东勇,周厚明,等.基于网络药理学和分子对接研究龙葵治疗肝癌的分子机制[J].中国中药杂志,2020,45(1):163-168.
[15] 蒋先仲.基于数据挖掘筛选植物类抗肝癌中药及抗肝癌组方思路探讨[J].广州中医药大学学报,2020,37(1):186-190.
[16] 杨永昌,贾志凌,张 颖,等.肿瘤标志物AFP-L3、AFP、AFU在原发性肝癌早期诊断中的应用评价[J].中国急救复苏与灾害医学杂志,2016,11(7):682-684.
[17] 郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析[J].陕西医学杂志,2019,48(7):850-852.
[18] 陆奕宇,陈晓乐,苏式兵.中医药诊治乙肝后肝硬化-肝癌恶性转化的研究进展[J].中医学,2019,8(6):359-366.
[19] 顾 欢,白长川,刘 柳, 等.中医药调控自噬治疗肝癌的研究现状[J].临床肝胆病杂志,2019,35(11):2582-2587.

相似文献/References:

[1]蒋海南,毛德文△,叶倩伶,等.中医辨证论治肝性脑病研究进展*[J].陕西中医,2020,(11):1678.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.042]
[2]王 军,徐建良,杜燕红.扶正祛邪汤对肝癌模型大鼠肠道菌群微生态环境的作用研究[J].陕西中医,2021,(2):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
　WANG Jun,XU Jianliang,DU Yanhong.Effect of Fuzheng Quxie decoction on intestinal microflora microecological environment of liver cancer model rats[J].,2021,(11):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
[3]朱玉辉,柴 劲.黄芪补气汤联合还原型谷胱甘肽对肝癌介入治疗后患者肝功能、氧化应激及炎症的影响[J].陕西中医,2021,(5):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
　ZHU Yuhui,CHAI Jin.Effect of Huangqi Buqi decoction combined with reduced glutathione on liver function,oxidative stress and inflammation after interventional therapy for hepatocellular carcinoma[J].,2021,(11):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
[4]刘振方,孙巧玉,孟祥彩,等.黄芩素下调微小RNA-130a抑制肝癌细胞侵袭机制研究[J].陕西中医,2021,(12):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
　LIU Zhenfang,SUN Qiaoyu,MENG Xiangcai,et al.Study on mechanism of baicalein down-regulating miR-130a to inhibit hepatocellular carcinoma invasion[J].,2021,(11):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
[5]乔林静,李志新,李国臣,等.李国臣从肝肾论治免疫性不孕症经验[J].陕西中医,2022,(3):360.[doi:DOI:10.3969/j.issn.1000-7369.2022.03.022]
　QIAO Linjing,LI Zhixin,LI Guochen,et al.LI Guochen's experience in treating immune infertility from liver and kidney[J].,2022,(11):360.[doi:DOI:10.3969/j.issn.1000-7369.2022.03.022]
[6]李武浩,许尤琪.中医药防治肝动脉灌注化疗相关不良反应研究进展[J].陕西中医,2022,(5):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
　LI Wuhao,XU Youqi.Clinical research progress of traditional Chinese medicine on the prevention and treatment of related adverse reaction of hepatic artery infusion chemotherapy[J].,2022,(11):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
[7]唐 枭,吴宇琪,何涛宏,等.曹吉勋治疗肛门术后难愈性创面经验[J].陕西中医,2022,(11):1600.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.026]
　TANG Xiao,WU Yuqi,HE Taohong,et al.CAO Jixun's experience in the treatment of refractory rounds after anus surgery[J].,2022,(11):1600.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.026]
[8]王文静,赵艳龙,曾晓荣,等.维持性血液透析患者微炎症状态中医诊疗进展[J].陕西中医,2023,(4):541.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.031]
　WANG Wenjing,ZHAO Yanlong,ZENG Xiaorong,et al.Progress of traditional Chinese medicine diagnosis and treatment of microinflammatory state in maintenance hemodialysis patients[J].,2023,(11):541.[doi:DOI:10.3969/j.issn.1000-7369.2023.04.031]
[9]陈 嵘,李淑敏,李旭华,等.软坚散结方调控小鼠HIF-1α 糖酵解分子转导抑制肝肿瘤细胞增殖机制研究[J].陕西中医,2023,(7):839.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
　CHEN Rong,LI Shumin,LI Xuhua,et al.Mechanism study on Ruanjian Sanjie prescription inhibit proliferation of liver cancer cells through regulating HIF-1α pathway[J].,2023,(11):839.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
[10]刘 鹏,陈青山,杨建波.柴胡疏肝散加减联合射频消融治疗肝癌疗效研究[J].陕西中医,2023,(7):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
　LIU Peng,CHEN Qingshan,YANG Jianbo.Curative effect study on Chaihu Shugan powder combined with radiofrequency ablation for liver cancer[J].,2023,(11):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]

备注/Memo

备注/Memo:
*国家中医药管理局“2018年全国名老中医药专家董克礼传承工作室”资助项目(国中医药人教函[2018]134号)；国家自然科学基金资助面上项目(81574101)；河南省重点研发与推广专项(202102310169)
更新日期/Last Update: 2020-11-09